Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers at Sanford Burnham Prebys Medical Discovery Institute and Harvard University discovered that mitochondria trigger senescence in cells by communicating with the cell's nucleus. They identified an FDA-approved drug that helped suppress the damaging effects of senescence in cells and mice, providing a potential treatment for a...
A new study reveals that MNT is required for the survival of MYC-driven lymphoma cells, suggesting a promising new approach for treating this type of cancer. Inhibiting MNT may also make tumours more susceptible to other drugs, offering hope for improved treatments.
Researchers at USC Viterbi School of Engineering designed a new drug combination that mimics glucose deprivation in cancer cells, leading to their death. The combination may have fewer side effects than traditional chemotherapies and reduce the incidence of acquired resistance.
A clinical trial has identified HIF-2α as a pivotal protein in the progression of clear cell renal cell carcinomas, which is susceptible to inhibition by PT2385. The study found that the drug effectively blocks cancer-promoting genes and starves tumors of blood.
Researchers are working on developing drugs that inhibit the function of NLRP3, an inflammatory protein involved in various diseases such as atherosclerosis, cancer, Alzheimer's, Parkinson's, and arthritis. Several NLRP3 inhibitors are currently in preclinical trials with varying mechanisms.
A randomized, double-blind trial compared the safety and efficacy of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma. F14512 demonstrated significant antitumor activity and clinical benefits, particularly in P-glycoprotein overexpressing lymphomas.
Researchers developed a smart material that can analyze multiple environment parameters to ensure effective drug delivery. The material achieves high sensitivity in detecting low concentrations of DNA, making it promising for express DNA analysis and next-generation drugs.
Researchers at Johns Hopkins Kimmel Cancer Center found that combining TAK228 and trametinib may be more effective than either drug alone in decreasing pediatric low-grade glioma growth. The combination therapy also suppressed activity in key cell signaling pathways, reducing tumor growth and increasing survival in mice.
Researchers found elevated risks of skin cancer, gastrointestinal and blood side effects, as well as liver test abnormalities and cirrhosis in participants taking low-dose methotrexate. The study provides a detailed side-effect profile that may inform more informed prescribing practices.
Researchers discovered that hyper-activation of Notch and Wnt signalling is connected to dysregulation of PRH protein, which controls genes and signaling pathways. By tailoring medication according to individual PRH expression levels, clinical efficacy may be improved for patients with bile duct cancer.
A new study provides an unprecedented look at the molecular steps of endometrial cancer, offering insights into tumor aggressiveness and patient responses to treatment. The research also suggests potential new roles for already-approved drugs targeting proteins like CDK12, SMARCA4, and PML in other types of cancer.
Researchers at City of Hope have discovered a link between the circadian rhythm gene BMAL1 and the suppression of tumor growth in obese and prediabetic mice. The study found that mice without the BMAL1 protein experienced accelerated breast tumor growth, suggesting that increasing BMAL1 levels may slow cancer progression.
Researchers at The Ohio State University Comprehensive Cancer Center argue that graphic warning labels can effectively promote an understanding of the consequences of smoking. The proposed labels, which include images and text warnings, have the potential to help reduce smoking rates and serve as a model for other regulatory efforts.
Researchers have designed new quinazolinone derivatives that effectively kill brain-eating amoebae, including Naegleria fowleri and Balamuthia mandrillaris. The compounds' low toxicity for human cells makes them promising candidates for drug development.
Researchers have designed a novel probiotic strain that can seek out solid tumors and safely deliver immune checkpoint inhibitors, leading to tumor regression. The probiotic platform can also be used to deliver multiple immunotherapies simultaneously, enabling effective therapeutic combinations for difficult-to-treat cancers.
Researchers at KAIST have discovered mechanisms that fuel a 'domino effect' in cancer drug resistance, enabling failed responses to paclitaxel to speed up the evolution of resistance to other drugs. The study suggests a new strategy for improving second-line cancer treatment.
Professor Lillian Siu receives TAT 2020 Honorary Award for her contributions to early drug development and phase I trials in head and neck malignancies. She advances the field of cancer drug development with innovative clinical trial designs and methodologies.
A type of micro RNA known as MIR1249 plays a key role in allowing bile duct cancers to resist chemotherapy. The researchers hope that targeting this molecule could make chemotherapy more effective.
Scientists have identified a peptide from the foot-and-mouth-disease virus that targets a protein on pancreatic cancer cells, allowing for highly potent drug delivery and complete tumour killing in mice. The research offers a promising new approach to treating pancreatic cancer with limited side effects.
A phase 2 randomized trial study found that patients who received the Triplex vaccine had 50% fewer CMV complications and developed immunity against the virus. The vaccine showed promise as a potential therapy for transplant recipients with weakened immune systems.
Research found that statins, alone or with metformin, increase survival in men with high-risk prostate cancer. Metformin plus statin was associated with a 36% reduction in risk of death compared to non-users, while statins alone showed a 54% reduction in PCA mortality among patients with high-risk prostate cancer.
Researchers discovered that combining alectinib with EGFR-inhibitors prevents CNS metastasis progression in mouse model. This combination treatment overcomes alectinib resistance, offering potential novel therapies for NSCLC and secondary cancers.
A new study creates personalized cancer vaccines that amplify the effects of immunotherapy, curing mice with treatment-resistant tumors. Researchers used a molecule called APOBEC3B to drive rapid genetic changes in cancer cells, creating unique signatures vulnerable to immune checkpoint blockade.
A study published in Addiction found that providing smokers with free, two-week nicotine replacement therapy (NRT) starter kits increased quit attempts and smoking abstinence. The intervention also showed promise for low-income patients, those with lower education levels, and rural residents.
Researchers have cataloged genetic fingerprints of DNA-damaging processes that drive cancer development, providing clues to how each cancer develops. This list allows scientists to search for previously unknown chemicals and biological pathways responsible for causing cancer.
A University of New Mexico Health Sciences Center-led research team has discovered a cancer-fighting compound that also reduces fat in obese mice. The team found that the compound, G-1, increases energy expenditure and targets brown fat cells, leading to weight loss and improved diabetes symptoms.
APG-157, a plant-based drug containing curcumin, was shown to reduce inflammation and attract immune cells to tumor tissues in patients with oral and oropharyngeal cancers. The treatment also decreased Bacteroides species and had no adverse effects.
A study of 125,500 Danish patients with atrial fibrillation found that those who experienced bleeding were between 11 and 24 times more likely to be diagnosed with bowel cancer. Patients who had gastrointestinal bleeding should always be offered meticulous clinical examination regardless of anticoagulant treatment.
A recent study cataloged genetic fingerprints of DNA-damaging processes driving cancer development, providing clues on how each cancer developed. The research will help understand cancer causes, inform prevention strategies, and signpost new directions for diagnosis and treatments.
A study of 140 older patients with non-metastatic cancer found that those with negative attitudes toward aging were more likely to die prematurely. Participants with a positive self-perception of aging had a significantly lower risk of death compared to their negative counterparts.
The Pan-Cancer Project has created the most comprehensive map of cancer genomes to date, improving our understanding of cancer and its diagnosis. Researchers have identified key regions controlling gene expression and discovered a 'carbon dating' method to pinpoint mutations in tumors years before they appear.
The Damon Runyon Cancer Research Foundation has awarded $231,000 in funding to 16 postdoctoral scientists conducting innovative cancer research projects. The Fellowship aims to encourage promising young scientists to pursue careers in cancer research.
A study suggests that combining NKTR-214 with adoptive cell therapy may produce a stronger immune response against advanced melanoma, increasing the number of anti-tumor immune cells and their lifespan. This approach could be effective for more patients with advanced solid tumors.
Researchers at Tokyo University of Science discovered a novel anti-cancer strategy targeting tumor-associated macrophages (TAMs) by regulating FROUNT protein. Disulfiram, an alcoholism treatment, was found to inhibit cancer cell growth and suppress TAM movement in animal experiments.
Researchers at the Francis Crick Institute have discovered the mechanism behind HIV's resistance to a widely-prescribed group of drugs. By exploring the structure of integrase using cryo-electron microscopy, they found that the virus can weaken the bond between the drug and its target, enabling its key enzyme to work again.
Researchers at Dartmouth's Norris Cotton Cancer Center have developed a non-invasive way to directly monitor oxygen distributions within cancer tumors during radiation therapy. The method uses specialty cameras and an oxygen probe drug injection to image the distribution of oxygen from within the tumor.
Researchers discover a drug already approved for cancer treatment can reverse symptoms of heart failure with preserved ejection fraction. The drug, SAHA, shows significant improvements in heart structure and function by reducing hypertrophy and increasing the heart's ability to pump blood.
Researchers analyzed over 23,000 human tumors and 1000 cancer cell lines to discover chromosome arm gains and losses can predict drug response better than genetic mutations. This finding has significant implications for personalized cancer treatments.
Researchers Dr. Leisha A. Emens and Dr. Xiang Zhang have received a Stand Up To Cancer Laura Ziskin Prize to explore the development of immune checkpoint inhibitors for breast cancer patients. Their collaboration aims to improve outcomes for breast cancer patients and reduce mortality rates.
Researchers found that highly innovative cancer drugs took 3.2 years longer to reach NHS patients than low-innovation treatments, highlighting a need for streamlined regulations and incentives for innovation. The study suggests that initiatives to prioritize the most innovative drugs have yet to be effective.
Researchers have developed iron nanowires that can selectively kill cancer cells while minimizing harm to healthy tissue. These nanorobots use an external magnetic field to guide themselves to the tumor site and activate a three-step mechanism that releases chemotherapy and generates heat, leading to nearly complete cell ablation.
FerriIridium, a novel drug, can diagnose and treat gastric cancer by selectively activating in tumor cells. The iron-based compound reduces side effects by targeting cancer cell mitochondria, leading to their destruction.
In 2019, the pharmaceutical industry approved 48 new medicines, including treatments for various cancers, sickle cell disease, and migraines. The majority of these drugs had novel mechanisms of action, such as antibody-drug conjugates and small interfering RNA.
The GW Cancer Center is conducting a phase II clinical trial examining the safety and effectiveness of Libtayo in reducing tumor size and preventing recurrence in high-risk cutaneous squamous cell carcinoma. The study aims to enroll over 75 participants and build on preliminary results from similar trials.
Researchers at Stanford University have developed a new kind of cancer drug inspired by antiviral treatments. Tests in mice show that these drugs can shrink tumors and prevent their spread, targeting cellular processes used by both viruses and some cancer cells.
Researchers create patient-specific, immune-active tumor organoids to test response to immunotherapy treatment and predict effectiveness. The platform has the potential to revolutionize cancer care by focusing on patients' unique needs.
Scientists at Karolinska Institutet have successfully designed small molecules that activate Frizzleds, a receptor family linked to various cancers and disorders. This breakthrough opens up new therapeutic strategies for treating different types of cancer.
Researchers have discovered ways to boost CAR T-cell therapy, surveying over 500 cancer drugs on its function. SMAC mimetics sensitize cancer cells to CAR T cells, while inhibiting CAR T cell functions could treat adverse effects.
A new technique developed at the University of Michigan uses bacteria to produce billions of different drug candidates that won't fall apart quickly inside the body. The peptides on bacteria are so plentiful that researchers can see how well they work right on the bacterium, enabling them to test hundreds of millions of different designs.
A study by the Broad Institute of MIT and Harvard uncovered nearly 50 non-oncology drugs that can kill cancer cells, including those for diabetes, inflammation, and arthritis. The researchers identified novel drug mechanisms and targets, suggesting a possible way to accelerate the development of new cancer drugs.
A new study reveals that certain enzymes, known as cathepsins, not only promote diseases like cancer but also cannibalize and deactivate each other. By modeling these interactions, researchers hope to develop more effective inhibitors with fewer side effects.
Research links proton pump inhibitors to poorer concentration and memory in breast cancer patients. Cognitive problems reported by PPI users were 20-29% more severe than those in non-users. The study suggests an association between PPI use and cognitive decline in breast cancer survivors.
Researchers found that estrogen regulates accumulation of immune cells in the liver, promoting tumor growth and immune suppression. The study suggests exploring sex hormones in female cancer patients and using anti-estrogen drugs to improve immunotherapy outcomes.
Researchers have designed modified red blood cells that can circulate for several weeks and target specific infections or diseases like cancer and Alzheimer's. These 'super-human' cells use a sticky surface to attach to bacteria and release antibiotics exactly where needed.
The Akay Lab has developed a new microfluidic brain cancer chip that can simultaneously administer multiple drugs and assess their response to glioblastoma cells. The device enables fast drug combination testing in as little as two weeks, potentially improving patient survival rates.
Researchers at UT Southwestern Medical Center identified a new mechanism by which clear cell renal cell carcinoma (ccRCC) tumors grow and spread. Inhibiting the enzyme TBK1, which becomes more active in these cancer cells, shows promise as a potential strategy for treating kidney cancer.
Researchers at Purdue University have developed an edible 'security tag' to protect prescription drugs from counterfeiting. The tag uses a digital fingerprint and can be scanned by a smartphone app to verify authenticity.
A research team at Dartmouth's Norris Cotton Cancer Center has identified VISTA as a molecule that regulates immunity and limits the damage it can cause. Blocking VISTA may enhance the host's ability to make protective tumor-specific immune responses, leading to potential therapeutic response to cancer.
Researchers have identified a promising drug candidate OT-82 that demonstrates remarkable efficacy in preclinical models. It targets the NAMPT enzyme responsible for NAD production, showing potential as a novel treatment option for refractory blood cancers.
Researchers at Ohio State University Wexner Medical Center suggest a new approach to treating advanced, progressing bile duct cancer. The study found that adding an mTOR inhibitor may re-sensitize tumor cells to FGFR inhibitors in patients who develop resistance to these agents.